Free Trial

hVIVO (HVO) Competitors

hVIVO logo
GBX 10.18 -0.08 (-0.73%)
As of 10:34 AM Eastern

HVO vs. FARN, VRP, ARIX, CIR, BVXP, 4BB, AVCT, TILS, VSN, and SCLP

Should you be buying hVIVO stock or one of its competitors? The main competitors of hVIVO include Faron Pharmaceuticals Oy (FARN), Verona Pharma plc (VRP.L) (VRP), Arix Bioscience (ARIX), Circassia Group (CIR), Bioventix (BVXP), 4basebio (4BB), Avacta Group (AVCT), Tiziana Life Sciences (TILS), Verseon (VSN), and Scancell (SCLP). These companies are all part of the "biotechnology" industry.

hVIVO vs. Its Competitors

hVIVO (LON:HVO) and Faron Pharmaceuticals Oy (LON:FARN) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, risk, institutional ownership, profitability, valuation and earnings.

hVIVO has a beta of 0.97, suggesting that its share price is 3% less volatile than the S&P 500. Comparatively, Faron Pharmaceuticals Oy has a beta of 0.36, suggesting that its share price is 64% less volatile than the S&P 500.

hVIVO has a net margin of 25.96% compared to Faron Pharmaceuticals Oy's net margin of 0.00%. hVIVO's return on equity of 47.93% beat Faron Pharmaceuticals Oy's return on equity.

Company Net Margins Return on Equity Return on Assets
hVIVO25.96% 47.93% 11.97%
Faron Pharmaceuticals Oy N/A 0.46%-70.00%

hVIVO has higher revenue and earnings than Faron Pharmaceuticals Oy. Faron Pharmaceuticals Oy is trading at a lower price-to-earnings ratio than hVIVO, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
hVIVO£68.74M1.05£17.84M£2.424.20
Faron Pharmaceuticals OyN/AN/A-£60.23M-£37.39-5.78

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
hVIVO
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Faron Pharmaceuticals Oy
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

34.9% of hVIVO shares are owned by institutional investors. Comparatively, 10.7% of Faron Pharmaceuticals Oy shares are owned by institutional investors. 14.0% of hVIVO shares are owned by company insiders. Comparatively, 31.8% of Faron Pharmaceuticals Oy shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Faron Pharmaceuticals Oy had 2 more articles in the media than hVIVO. MarketBeat recorded 2 mentions for Faron Pharmaceuticals Oy and 0 mentions for hVIVO. Faron Pharmaceuticals Oy's average media sentiment score of 0.46 beat hVIVO's score of 0.00 indicating that Faron Pharmaceuticals Oy is being referred to more favorably in the news media.

Company Overall Sentiment
hVIVO Neutral
Faron Pharmaceuticals Oy Neutral

Summary

hVIVO beats Faron Pharmaceuticals Oy on 11 of the 14 factors compared between the two stocks.

Get hVIVO News Delivered to You Automatically

Sign up to receive the latest news and ratings for HVO and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HVO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

HVO vs. The Competition

MetrichVIVOBiotechnology IndustryMedical SectorLON Exchange
Market Cap£72.00M£128.71M£5.59B£3.00B
Dividend Yield1.10%3.74%5.25%5.02%
P/E Ratio4.203.4127.54149.52
Price / Sales1.054,294.34415.83241,371.90
Price / Cash4.9413.1937.0627.97
Price / Book1.8341.588.104.56
Net Income£17.84M-£92.15M£3.17B£5.90B
7 Day Performance-7.31%1.11%3.33%7.37%
1 Month Performance-13.53%3.02%3.54%11.19%
1 Year Performance-62.66%174.99%33.62%81.05%

hVIVO Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
HVO
hVIVO
N/AGBX 10.18
-0.7%
N/A-61.4%£72.00M£68.74M4.20N/A
FARN
Faron Pharmaceuticals Oy
N/AGBX 214
-0.5%
N/A+116.2%£287.30MN/A-5.7234News Coverage
Positive News
Gap Up
VRP
Verona Pharma plc (VRP.L)
N/AN/AN/AN/A£228MN/A-1.6822News Coverage
Gap Up
ARIX
Arix Bioscience
N/AN/AN/AN/A£183.73M£14.16M1,290.919
CIR
Circassia Group
N/AN/AN/AN/A£142.66M£27.90M3,400.00111Gap Down
BVXP
Bioventix
N/AGBX 2,650
-1.1%
N/A-38.2%£138.76M£13.65M17.1412News Coverage
4BB
4basebio
1.8449 of 5 stars
GBX 1,005
+0.5%
GBX 1,600
+59.2%
-34.4%£128.74M£311K-1,288.46101
AVCT
Avacta Group
N/AGBX 32
+1.6%
N/A-57.0%£121.57M£26.29M-4.12120
TILS
Tiziana Life Sciences
N/AN/AN/AN/A£113.85M-£3.60M-3.5911
VSN
Verseon
N/AN/AN/AN/A£112.24MN/A-5.17N/AGap Up
SCLP
Scancell
N/AGBX 10
-3.8%
N/A+3.9%£103.57MN/A-15.3351Gap Down

Related Companies and Tools


This page (LON:HVO) was last updated on 7/10/2025 by MarketBeat.com Staff
From Our Partners